DK1719509T3 - Anvendelse af 2,5-dihydroxybenzensulfonsyre til fremstilling af medikamenter til behandling af angiogeneseafhængige sygdomme såsom cancer og psoriasis - Google Patents

Anvendelse af 2,5-dihydroxybenzensulfonsyre til fremstilling af medikamenter til behandling af angiogeneseafhængige sygdomme såsom cancer og psoriasis

Info

Publication number
DK1719509T3
DK1719509T3 DK05708114.3T DK05708114T DK1719509T3 DK 1719509 T3 DK1719509 T3 DK 1719509T3 DK 05708114 T DK05708114 T DK 05708114T DK 1719509 T3 DK1719509 T3 DK 1719509T3
Authority
DK
Denmark
Prior art keywords
treatment
psoriasis
medicaments
compounds
cancer
Prior art date
Application number
DK05708114.3T
Other languages
English (en)
Inventor
Garrido Antonio Romero
Sanchez Pedro Cuevas
Lopez Serafin Valverde
Puerto Rosa Maria Lozano
Gallego Guillermo Gimenez
Original Assignee
Action Medicines Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Action Medicines Sl filed Critical Action Medicines Sl
Application granted granted Critical
Publication of DK1719509T3 publication Critical patent/DK1719509T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK05708114.3T 2004-02-17 2005-02-16 Anvendelse af 2,5-dihydroxybenzensulfonsyre til fremstilling af medikamenter til behandling af angiogeneseafhængige sygdomme såsom cancer og psoriasis DK1719509T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200400371A ES2238924B1 (es) 2004-02-17 2004-02-17 Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes.
PCT/ES2005/070017 WO2005077352A1 (es) 2004-02-17 2005-02-16 Uso del ácido 2,5-dihidroxibencenosulfónico, en la fabricación de medicamentos de aplicación en el tratamiento de enfermedades angiogénicas como el cáncer y la psoriasis

Publications (1)

Publication Number Publication Date
DK1719509T3 true DK1719509T3 (da) 2010-02-08

Family

ID=34854892

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05708114.3T DK1719509T3 (da) 2004-02-17 2005-02-16 Anvendelse af 2,5-dihydroxybenzensulfonsyre til fremstilling af medikamenter til behandling af angiogeneseafhængige sygdomme såsom cancer og psoriasis

Country Status (17)

Country Link
US (3) US7968531B2 (da)
EP (1) EP1719509B1 (da)
JP (4) JP4892360B2 (da)
KR (1) KR20070007783A (da)
CN (1) CN101014330A (da)
AT (1) ATE444743T1 (da)
AU (1) AU2005211956B2 (da)
CA (1) CA2555248C (da)
DE (1) DE602005017015D1 (da)
DK (1) DK1719509T3 (da)
ES (2) ES2238924B1 (da)
IL (1) IL177238A (da)
MX (1) MXPA06009295A (da)
PT (1) PT1719509E (da)
RU (1) RU2006133305A (da)
UA (1) UA86399C2 (da)
WO (1) WO2005077352A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070149618A1 (en) 2004-02-17 2007-06-28 Action Medicines, S.L. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
US20080125485A1 (en) 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
ES2238924B1 (es) * 2004-02-17 2006-12-01 Investread Europa, S.L. Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes.
US8541467B2 (en) * 2006-08-16 2013-09-24 Action Medicines, S.L. Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ
PT2054051E (pt) * 2006-08-16 2013-04-03 Amderma Pharmaceuticals Llc Utilização de derivados 2,5-di-hidroxibenzeno para tratar ceratose actínica
ES2315118B1 (es) * 2006-08-16 2009-12-30 Action Medicines, S.L. Uso de los compuestos y derivados 2,5-dihidroxibencenicos en la preparacion de medicamentos utiles en el tratamiento de rosacea y psoriasis.
WO2008113863A2 (en) * 2007-03-22 2008-09-25 Action Medicines, S.L. Nitrosated derivatives of 2,5-dihydroxybenzene compounds
WO2009083940A2 (en) * 2008-01-03 2009-07-09 Action Medicines S.L. Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts
WO2009103069A1 (en) 2008-02-15 2009-08-20 Osborne David W Skin penetration enhancing systems for polar drugs
CN110092736A (zh) * 2018-12-05 2019-08-06 湖北广辰药业有限公司 一种减少羟苯双磺酸钙杂质含量的羟苯磺酸钙制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954767A (en) * 1972-05-17 1976-05-04 Esteve Subirana Antonio Piperazine salts of 2,5-dihydroxy benzene sulfonic acid mono- and diesters
US4115648A (en) * 1974-09-13 1978-09-19 Laboratorios Del Dr. Esteve, S.A. 2,5-Dihydroxy benzene sulfonic acid mono esters
ATE69548T1 (de) 1985-05-15 1991-12-15 Roshdy Ismail Vitamin e-haltiges mittel zur verbesserung der eigenschaften des blutes.
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
GB8620073D0 (en) * 1986-08-18 1986-10-01 Delandale Lab Ltd Pharmaceutical compositions
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE4230262A1 (de) * 1992-09-10 1994-03-17 Behringwerke Ag Substituierte Phenole, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von zellproliferationsbedingten Erkrankungen
US5374772A (en) 1992-12-08 1994-12-20 Hoffmann-Laroche Inc. Substituted benzoic acids, inhibitors of phospholipases A2
FR2717078B1 (fr) * 1994-03-08 1996-12-13 Oreal Utilisation des acides sulfoniques comme agents antivieillissement dans une composition cosmétique ou dermatologique.
WO1996017589A1 (en) 1994-12-08 1996-06-13 Kao Corporation Method of smoothing or removing wrinkles and method of stimulating collagen synthesis
US5610185A (en) 1995-02-17 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Method for the treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein cross-linking compounds
JPH08283152A (ja) 1995-04-12 1996-10-29 Kao Corp 細胞接着抑制剤
FR2782269B1 (fr) * 1998-08-17 2001-08-31 Oreal Composition cosmetique et/ou dermatologique contenant de l'acide salicylique ou un derive d'acide salicylique et son utilisation
US6258821B1 (en) * 1999-04-26 2001-07-10 Medimmune Oncology, Inc. Compositions comprising trimetrexate and methods of their synthesis and use
US6787573B2 (en) * 1999-07-02 2004-09-07 Universiteit Utrecht Antiviral therapy
GB9927629D0 (en) * 1999-11-24 2000-01-19 Croda Int Plc Compounds
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
EP1457485A1 (en) * 2003-03-14 2004-09-15 Dompé S.P.A. Sulfonic acids, their derivatives and pharmaceutical compositions containing them
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
US20050175559A1 (en) * 2004-02-10 2005-08-11 Pcr Technology Holdings, Lc Method and preparation for reducing skin hyperpigmentation
ES2238924B1 (es) * 2004-02-17 2006-12-01 Investread Europa, S.L. Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes.
US20070149618A1 (en) * 2004-02-17 2007-06-28 Action Medicines, S.L. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
US20080125485A1 (en) * 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
CA2579784C (en) 2004-09-14 2013-02-26 Ajinomoto Omnichem S.A. Topical compositions containing phosphorylated polyphenols
EP1676573A1 (en) 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor
US20080114063A1 (en) * 2006-08-16 2008-05-15 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for the Treatment of Tissue Reactive Diseases
PT2054051E (pt) * 2006-08-16 2013-04-03 Amderma Pharmaceuticals Llc Utilização de derivados 2,5-di-hidroxibenzeno para tratar ceratose actínica
US8541467B2 (en) * 2006-08-16 2013-09-24 Action Medicines, S.L. Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ

Also Published As

Publication number Publication date
AU2005211956B2 (en) 2011-07-28
KR20070007783A (ko) 2007-01-16
ES2334447T3 (es) 2010-03-10
CA2555248C (en) 2013-04-16
UA86399C2 (ru) 2009-04-27
ES2238924A1 (es) 2005-09-01
ES2238924B1 (es) 2006-12-01
JP4892360B2 (ja) 2012-03-07
JP2007522256A (ja) 2007-08-09
JP6216826B2 (ja) 2017-10-18
CN101014330A (zh) 2007-08-08
US20120142780A1 (en) 2012-06-07
RU2006133305A (ru) 2008-03-27
US20130203851A1 (en) 2013-08-08
JP5639029B2 (ja) 2014-12-10
AU2005211956A1 (en) 2005-08-25
IL177238A0 (en) 2006-12-10
EP1719509A1 (en) 2006-11-08
JP2016145243A (ja) 2016-08-12
PT1719509E (pt) 2010-01-13
US20080293816A1 (en) 2008-11-27
US8435971B2 (en) 2013-05-07
JP2014240445A (ja) 2014-12-25
WO2005077352A1 (es) 2005-08-25
IL177238A (en) 2013-06-27
CA2555248A1 (en) 2005-08-25
ATE444743T1 (de) 2009-10-15
EP1719509B1 (en) 2009-10-07
US7968531B2 (en) 2011-06-28
JP2012012413A (ja) 2012-01-19
JP5973518B2 (ja) 2016-08-23
DE602005017015D1 (de) 2009-11-19
MXPA06009295A (es) 2007-03-23

Similar Documents

Publication Publication Date Title
DK1719509T3 (da) Anvendelse af 2,5-dihydroxybenzensulfonsyre til fremstilling af medikamenter til behandling af angiogeneseafhængige sygdomme såsom cancer og psoriasis
UY28473A1 (es) Nuevos compuestos
CY1114272T1 (el) Υποκατεστημενες διυδροπυραζολονες για την θεραπευτικη αντιμετωπιση των καρδιαγγειακων και αιματολογικων παθησεων
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
CY1108292T1 (el) Αντικαρκινικο σκευασμα που περιεχει dmxaa
ATE417610T1 (de) Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
CY2013021I1 (el) Συνθεσεις για τη θεραπευτικη αγωγη γαστροεντερικων διαταραχων
CY1109925T1 (el) Η χρηση πυριδυλ αμιδιων ως παρεμποδιστων της αγγειογενεσης
ZA200606177B (en) 3-'4-heterocyclyl-1,2,3,-triazol-1-yl'-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases
ATE320426T1 (de) Harnstoffderivate und ihre verwendung
MX2010004026A (es) Piperidino-dihidrotienopirimidinas sustituidas.
CY1111651T1 (el) Παραγωγα 3-(ετεροαρυλ-oξυ)-2-αλκυλ-1-αζα- δικυκλοαλκυλιου ως συνδετες του αλφα.7-nachr για τη θεραπεια των ασθενειων του κνς
WO2007059905A3 (en) Thienopyrimidines treating inflammatory diseases
CY1108105T1 (el) Ιβανδρονικο οξυ για την θεραπευτικη αντιμετωπιση και την προληψη της οστεoπορωσης
ZA200803327B (en) Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
BRPI0513379A (pt) derivados de sulfonamida
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
NZ597857A (en) Method and composition for treating mucosal disorders
ECSP055844A (es) Nuevos compuestos triciclicos
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
NO20055307D0 (no) Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer
DE602007008385D1 (de) Verwendung von valproinsäure zur topischen behandlung von leichter bis mittelschwerer akne vulgaris
NO20082566L (no) Kombinasjon av AZ2171 og permetrexed
DK1845990T3 (da) Behandling af metastaserede tumorer
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК